[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565781":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":19,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":7,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Akshay Sharma, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","8662785833","referralinfo@stjude.org",{"name":18,"role":14,"phone":15,"phoneExt":7,"email":16},"Neha Das Gupta, PhD",[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Memphis","Tennessee","38105","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-90.04898,35.14953,{"lat":31,"lon":30},[34],{"name":35,"role":14,"phone":36,"phoneExt":7,"email":16},"Sharma Akshay, MD","866-278-5833",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100565781","long-term-follow-up-study-for-individuals-with-hemoglobin-disorders-after-hematopoietic-cell-transplant-or-gene-therapy-100565781",false,"NCT06646640","Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy","Inclusion Criteria:\n\n* Receipt, or planned receipt, of an allogeneic HSCT or infusion of genetically modified autologous cells for hemoglobin disorders within 15 years prior to enrollment\n\nExclusion Criteria:\n\n* Inability or unwillingness of research participant and\u002For legal guardian\u002F representative to provide written informed consent.","ALL",{"count":47,"type":48},200,"ESTIMATED","OBSERVATIONAL","This is a prospective, longitudinal, non-therapeutic study which includes routine assessment for long-term effects, as per FDA guidelines after receipt of an allogeneic HCT or autologous genetically modified cellular products for hemoglobin disorders.\n\nPrimary objective:\n\n\\- To provide long term follow up, for individuals with hemoglobin disorders undergoing allogeneic hematopoietic stem cell transplantation (HCT) or receipt of an autologous genetically modified cellular product to treat their hemoglobinopathy. For individuals receiving a genetically modified cellular product, this long term follow up study is in accordance with the guidelines provided by the Food and Drug Administration (FDA).",[52],"Hemoglobin Disorder",[54,55],"Transplant","Gene Therapy","2025-08-01",{"date":58,"type":59},"2025-08-07","ACTUAL",{"date":61,"type":59},"2025-06-26",{"date":63,"type":48},"2050-01",{"name":5,"class":6},1]